Cargando…
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration
We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 m...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569099/ https://www.ncbi.nlm.nih.gov/pubmed/28835685 http://dx.doi.org/10.1038/s41598-017-09632-0 |
| _version_ | 1783258923820646400 |
|---|---|
| author | Yamashiro, Kenji Mori, Keisuke Honda, Shigeru Kano, Mariko Yanagi, Yasuo Obana, Akira Sakurada, Yoichi Sato, Taku Nagai, Yoshimi Hikichi, Taiichi Kataoka, Yasushi Hara, Chikako Koyama, Yasurou Koizumi, Hideki Yoshikawa, Munemitsu Miyake, Masahiro Nakata, Isao Tsuchihashi, Takashi Horie-Inoue, Kuniko Matsumiya, Wataru Ogasawara, Masashi Obata, Ryo Yoneyama, Seigo Matsumoto, Hidetaka Ohnaka, Masayuki Kitamei, Hirokuni Sayanagi, Kaori Ooto, Sotaro Tamura, Hiroshi Oishi, Akio Kabasawa, Sho Ueyama, Kazuhiro Miki, Akiko Kondo, Naoshi Bessho, Hiroaki Saito, Masaaki Takahashi, Hidenori Tan, Xue Azuma, Keiko Kikushima, Wataru Mukai, Ryo Ohira, Akihiro Gomi, Fumi Miyata, Kazunori Takahashi, Kanji Kishi, Shoji Iijima, Hiroyuki Sekiryu, Tetsuju Iida, Tomohiro Awata, Takuya Inoue, Satoshi Yamada, Ryo Matsuda, Fumihiko Tsujikawa, Akitaka Negi, Akira Yoneya, Shin Iwata, Takeshi Yoshimura, Nagahisa |
| author_facet | Yamashiro, Kenji Mori, Keisuke Honda, Shigeru Kano, Mariko Yanagi, Yasuo Obana, Akira Sakurada, Yoichi Sato, Taku Nagai, Yoshimi Hikichi, Taiichi Kataoka, Yasushi Hara, Chikako Koyama, Yasurou Koizumi, Hideki Yoshikawa, Munemitsu Miyake, Masahiro Nakata, Isao Tsuchihashi, Takashi Horie-Inoue, Kuniko Matsumiya, Wataru Ogasawara, Masashi Obata, Ryo Yoneyama, Seigo Matsumoto, Hidetaka Ohnaka, Masayuki Kitamei, Hirokuni Sayanagi, Kaori Ooto, Sotaro Tamura, Hiroshi Oishi, Akio Kabasawa, Sho Ueyama, Kazuhiro Miki, Akiko Kondo, Naoshi Bessho, Hiroaki Saito, Masaaki Takahashi, Hidenori Tan, Xue Azuma, Keiko Kikushima, Wataru Mukai, Ryo Ohira, Akihiro Gomi, Fumi Miyata, Kazunori Takahashi, Kanji Kishi, Shoji Iijima, Hiroyuki Sekiryu, Tetsuju Iida, Tomohiro Awata, Takuya Inoue, Satoshi Yamada, Ryo Matsuda, Fumihiko Tsujikawa, Akitaka Negi, Akira Yoneya, Shin Iwata, Takeshi Yoshimura, Nagahisa |
| author_sort | Yamashiro, Kenji |
| collection | PubMed |
| description | We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8,480,849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of <5 × 10(−6) were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment. |
| format | Online Article Text |
| id | pubmed-5569099 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55690992017-09-01 A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration Yamashiro, Kenji Mori, Keisuke Honda, Shigeru Kano, Mariko Yanagi, Yasuo Obana, Akira Sakurada, Yoichi Sato, Taku Nagai, Yoshimi Hikichi, Taiichi Kataoka, Yasushi Hara, Chikako Koyama, Yasurou Koizumi, Hideki Yoshikawa, Munemitsu Miyake, Masahiro Nakata, Isao Tsuchihashi, Takashi Horie-Inoue, Kuniko Matsumiya, Wataru Ogasawara, Masashi Obata, Ryo Yoneyama, Seigo Matsumoto, Hidetaka Ohnaka, Masayuki Kitamei, Hirokuni Sayanagi, Kaori Ooto, Sotaro Tamura, Hiroshi Oishi, Akio Kabasawa, Sho Ueyama, Kazuhiro Miki, Akiko Kondo, Naoshi Bessho, Hiroaki Saito, Masaaki Takahashi, Hidenori Tan, Xue Azuma, Keiko Kikushima, Wataru Mukai, Ryo Ohira, Akihiro Gomi, Fumi Miyata, Kazunori Takahashi, Kanji Kishi, Shoji Iijima, Hiroyuki Sekiryu, Tetsuju Iida, Tomohiro Awata, Takuya Inoue, Satoshi Yamada, Ryo Matsuda, Fumihiko Tsujikawa, Akitaka Negi, Akira Yoneya, Shin Iwata, Takeshi Yoshimura, Nagahisa Sci Rep Article We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8,480,849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of <5 × 10(−6) were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment. Nature Publishing Group UK 2017-08-23 /pmc/articles/PMC5569099/ /pubmed/28835685 http://dx.doi.org/10.1038/s41598-017-09632-0 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Article Yamashiro, Kenji Mori, Keisuke Honda, Shigeru Kano, Mariko Yanagi, Yasuo Obana, Akira Sakurada, Yoichi Sato, Taku Nagai, Yoshimi Hikichi, Taiichi Kataoka, Yasushi Hara, Chikako Koyama, Yasurou Koizumi, Hideki Yoshikawa, Munemitsu Miyake, Masahiro Nakata, Isao Tsuchihashi, Takashi Horie-Inoue, Kuniko Matsumiya, Wataru Ogasawara, Masashi Obata, Ryo Yoneyama, Seigo Matsumoto, Hidetaka Ohnaka, Masayuki Kitamei, Hirokuni Sayanagi, Kaori Ooto, Sotaro Tamura, Hiroshi Oishi, Akio Kabasawa, Sho Ueyama, Kazuhiro Miki, Akiko Kondo, Naoshi Bessho, Hiroaki Saito, Masaaki Takahashi, Hidenori Tan, Xue Azuma, Keiko Kikushima, Wataru Mukai, Ryo Ohira, Akihiro Gomi, Fumi Miyata, Kazunori Takahashi, Kanji Kishi, Shoji Iijima, Hiroyuki Sekiryu, Tetsuju Iida, Tomohiro Awata, Takuya Inoue, Satoshi Yamada, Ryo Matsuda, Fumihiko Tsujikawa, Akitaka Negi, Akira Yoneya, Shin Iwata, Takeshi Yoshimura, Nagahisa A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title | A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_full | A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_fullStr | A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_full_unstemmed | A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_short | A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_sort | prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569099/ https://www.ncbi.nlm.nih.gov/pubmed/28835685 http://dx.doi.org/10.1038/s41598-017-09632-0 |
| work_keys_str_mv | AT yamashirokenji aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT morikeisuke aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hondashigeru aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kanomariko aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yanagiyasuo aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT obanaakira aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sakuradayoichi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT satotaku aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT nagaiyoshimi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hikichitaiichi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kataokayasushi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT harachikako aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT koyamayasurou aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT koizumihideki aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoshikawamunemitsu aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT miyakemasahiro aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT nakataisao aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tsuchihashitakashi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT horieinouekuniko aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT matsumiyawataru aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ogasawaramasashi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT obataryo aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoneyamaseigo aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT matsumotohidetaka aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ohnakamasayuki aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kitameihirokuni aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sayanagikaori aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ootosotaro aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tamurahiroshi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT oishiakio aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kabasawasho aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ueyamakazuhiro aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT mikiakiko aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kondonaoshi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT besshohiroaki aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT saitomasaaki aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takahashihidenori aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tanxue aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT azumakeiko aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kikushimawataru aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT mukairyo aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ohiraakihiro aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT gomifumi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT miyatakazunori aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takahashikanji aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kishishoji aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT iijimahiroyuki aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sekiryutetsuju aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT iidatomohiro aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT awatatakuya aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT inouesatoshi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yamadaryo aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT matsudafumihiko aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tsujikawaakitaka aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT negiakira aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoneyashin aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT iwatatakeshi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoshimuranagahisa aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yamashirokenji prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT morikeisuke prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hondashigeru prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kanomariko prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yanagiyasuo prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT obanaakira prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sakuradayoichi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT satotaku prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT nagaiyoshimi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hikichitaiichi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kataokayasushi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT harachikako prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT koyamayasurou prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT koizumihideki prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoshikawamunemitsu prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT miyakemasahiro prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT nakataisao prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tsuchihashitakashi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT horieinouekuniko prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT matsumiyawataru prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ogasawaramasashi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT obataryo prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoneyamaseigo prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT matsumotohidetaka prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ohnakamasayuki prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kitameihirokuni prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sayanagikaori prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ootosotaro prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tamurahiroshi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT oishiakio prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kabasawasho prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ueyamakazuhiro prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT mikiakiko prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kondonaoshi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT besshohiroaki prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT saitomasaaki prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takahashihidenori prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tanxue prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT azumakeiko prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kikushimawataru prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT mukairyo prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ohiraakihiro prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT gomifumi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT miyatakazunori prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takahashikanji prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kishishoji prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT iijimahiroyuki prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sekiryutetsuju prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT iidatomohiro prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT awatatakuya prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT inouesatoshi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yamadaryo prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT matsudafumihiko prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tsujikawaakitaka prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT negiakira prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoneyashin prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT iwatatakeshi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoshimuranagahisa prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration |